Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunkovir in mild to moderate COVID-19
NCT05249777Phase 3Completed
- Sponsor
- Sao Thai Duong Joint Stock Company
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing TD0069 Arm with Placebo Arm (2 arms). Primary endpoints: The rate of patients with serious diseases/conditions related to Covid-19 at 28 days, Daily symptoms improvement at 14 days and 2 more. Started Jan 2022; status: completed.
02
Drugs
KOVIR
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05249777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249777.